Radiolabeled peptide therapy beats everolimus on progression-free survival in COMPETE

What happened

COMPETE directly compared peptide receptor radionuclide therapy with everolimus in adults with advanced, progressive, somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors. The open-label phase 3 trial enrolled across 49 specialist centers in 14 countries and randomized 309 patients.

What the study found

Median progression-free survival was 23.9 months with lutetium-177 edotreotide and 14.1 months with everolimus. The stratified hazard ratio was 0.67. Treatment-related grade 3 or 4 adverse events occurred in 18% of patients in the radiolabeled-peptide group and 40% in the everolimus group; no treatment-related deaths were reported.

Evidence check

This is randomized phase 3 evidence with blinded central review of the primary endpoint, supporting an A grade for the comparative progression claim. The trial was open label, and its findings apply to the enrolled grade 1 or 2, receptor-positive disease population—not to cancer generally. Progression-free survival is also distinct from overall survival.

Why it matters

The peptide is functioning as a molecular address: it targets somatostatin receptors and carries radiation to tumor tissue. The result provides rare head-to-head sequencing evidence in a field where both options were already established. Treatment choice still requires specialist assessment of receptor status, disease pattern, marrow and kidney considerations.

What the study design can—and cannot—show

The source addressing “Radiolabeled peptide therapy beats everolimus on progression-free survival in COMPETE” is identified as a multicenter randomized phase 3 trial. Random allocation can reduce important sources of bias and makes a causal interpretation more credible. It does not remove uncertainty created by a small sample, short follow-up, selective endpoints, attrition, or a population that differs from the patients who may eventually use an intervention. The relevant unit of evidence is the result produced by this design, not the ambition implied by the topic or headline.

Why the evidence grade matters

Vitalspan Wire assigns this article about “Radiolabeled peptide therapy beats everolimus on progression-free survival in COMPETE” evidence grade A. An A grade means the narrow claim reported here is supported by strong human evidence or an authoritative primary record. It is not a declaration that every related intervention is effective, that every patient will benefit, or that safety questions are permanently closed. The grade should change if later evidence materially changes the record. The grade applies to the central claim in this article; it is not a score for The Lancet, the research team, or the wider field.

The responsible reading

Peptide coverage requires unusual attention to molecular identity and translation. A named sequence, salt, formulation, delivery route, or manufactured product cannot automatically borrow evidence from another version. For Radiolabeled peptide therapy beats everolimus on progression-free survival in COMPETE, the defensible conclusion is the one supported by the specific material and experimental setting described in the primary source. Readers should use the linked primary record to inspect the authors’ methods and conclusions directly. Important decisions about diagnosis, treatment, dosing, or stopping prescribed care belong with a qualified clinician who can evaluate individual circumstances.